From PsychonautWiki
(Redirected from 5-meo-dibf)
Jump to navigation Jump to search
Summary sheet: 5-MeO-DiBF
Chemical Nomenclature
Common names 5-MeO-DiBF
Systematic name 2-(5-Methoxy-1-benzofuran-3-yl)-N,N-diisopropyllethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Benzofuran
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 20 mg
Light 50 - 80 mg
Common 80 - 110 mg
Strong 110 - 140 mg
Heavy 140 mg +
Total 4 - 6 hours
Peak 30 - 60 minutes

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


5-Methoxy-N,N-diisopropylbenzofuranethylamine (also known as 5-MeO-DiBF) is a novel psychedelic substance of the benzofuran class that produces psychedelic and stimulating effects when administered.[1] It is related in structure to 5-MeO-DiPT.

This compound has little to no history of human usage prior to its September 2015 release on the online research chemical market.

Very little is known about the pharmacological properties, metabolism, and toxicity of 5-MeO-DiBF. Due to its extreme novelty and unknown toxicity profile, it is highly advised that one use harm reduction practices if using this substance.


5-MeO-DiBF, or 5-methoxy-N,N-diisopropylbenzofuranethylamine, is a synthetic heterocyclic alkaloid molecule of the benzofuran class. Benzofuran is a bicyclic structure formed by the fusion of a benzene ring and a furan ring, a five member aromatic ring containing an oxygen substituent.

5-MeO-DiBF is composed of a benzofuran group attached at R3 to an amino group via an ethyl side chain. It is substituted at R5 of the benzofuran heterocycle with a methoxy (MeO) functional group CH3O−; it also contains two isopropyl chains bound to the terminal amine RN of its tryptamine backbone (DiBF).

The benzofuran group of 5-MeO-DiBF is closely related in structure to the indole found in tryptamines; benzofuran contains an oxygen group at the same location that indole contains a nitrogen. As such, 5-MeO-DiBF is closely related in structure to the psychedelic tryptamine 5-MeO-DiPT. 5-MeO-DiBF is the benzofuran analogue of 5-MeO-DiPT.


Further information: Serotonergic psychedelic

5-MeO-DiBF likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from its efficacy at the 5-HT1A and 5-HT2 family of serotonin receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

This compound is several times less potent as a serotonin agonist than 5-MeO-DiPT. It has relatively more activity at 5-HT1A, but still shows strongest effects at the 5-HT2 family of receptors.[2][3]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 5-MeO-DiBF use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-DiBF is a research chemical with very little history of human usage.

Anecdotal reports from those who have tried 5-MeO-DiBF suggest that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

5-MeO-DiBF is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 5-MeO-DiBF is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-DiBF presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-DiBF all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

5-MeO-DiBF is currently thought to be a legal grey area substace in many parts of the world. However, although it is easily accessible through the use of online research chemical vendors, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.

  • Germany: 5-MeO-DiBF is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016.[5][6] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[7]
  • Switzerland: 5-MeO-DiBF is a controlled substance specifically named under Verzeichnis E.[8]
  • United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[9]

See also

External links



  1. The Characterization of 2-(5-Methoxy-1-benzofuran-3-yl)-N,N-dimethylethanamine (5-MeO-BFE) and Differentiation from its N-Ethyl Analog (Microgram Journal 2012;9(1):39-45) 
  2. Tomaszewski, Z., Johnson, M. P., Huang, X., Nichols, D. E. (29 May 1992). "Benzofuran bioisosteres of hallucinogenic tryptamines". Journal of Medicinal Chemistry. 35 (11): 2061–2064. doi:10.1021/jm00089a017. ISSN 0022-2623. 
  3. McKenna, D. J., Repke, D. B., Lo, L., Peroutka, S. J. (March 1990). "Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes". Neuropharmacology. 29 (3): 193–198. doi:10.1016/0028-3908(90)90001-8. ISSN 0028-3908. 
  4. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  5. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019. 
  6. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  7. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  8. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  9. Psychoactive Substances Act 2016